Clinical Trials Logo
  1. Home
  2. Palmoplantar Pustulosis
  3. NCT05194839

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Palmoplantar Pustulosis Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis

Clinical Trial Summary

A 12-week Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis followed by an Open-label Extension Phase.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05194839
Study type Interventional
Source Aristea Therapeutics, Inc.
Contact
Status Terminated
Phase Phase 2
Start date January 5, 2022
Completion date March 6, 2023
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04493424 - A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab Phase 2
Recruiting NCT05994976 - Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Completed NCT04572997 - Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS) Phase 2
Completed NCT03633396 - A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis Phase 2
Active, not recruiting NCT05174065 - Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP) Phase 3
Active, not recruiting NCT04459507 - A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan
Completed NCT01780857 - Immune Signature of Palmoplantar Pustulosis N/A
Completed NCT03972280 - Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis Phase 1
Completed NCT01794117 - Anakinra for Inflammatory Pustular Skin Diseases Phase 2
Recruiting NCT05710185 - Deucravacitinib for the Treatment of Palmoplantar Pustulosis Phase 4
Active, not recruiting NCT04566471 - Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence
Completed NCT03988335 - A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) Phase 2
Completed NCT02641730 - An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis Phase 3
Completed NCT04061252 - A Study of KHK4827 in Subjects With Palmoplantar Pustulosis Phase 3